Skip to content

Released Mar 9, 2023, before the open

10-K filed Mar 9, 2023, 68 days after period end · 0001628280-23-007297

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$4.18Mderived+486.8% vs Q4 2021−36.9% vs Q3 2022
Net Income-$28.89MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$31,886,000N/M
Operating Cash Flowderived-$28,924,000N/M
Free Cash Flowderived-$29,193,000N/M
Margins · derived
Operating margin-762.1%+3176.5 pt vs Q4 2021
Net margin-690.4%+3397.0 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$4.18M$713.00K$251.00K—
Net Income-$28.89M-$29.14M-$20.76M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR